Name | brimonidine |
---|---|
Synonyms |
brimonidinum
5-bromo-6-(imidazolin-2-ylamino)-quinoxaline MFCD00153878 Brimonidine [INN:BAN] Bromoxidine Brimonidine 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline UNII-E6GNX3HHTE [3H]-Brimonidine 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- UK 14,304 brimonidina |
Description | Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist. |
---|---|
Related Catalog | |
Target |
α2-adrenergic Receptor. |
In Vitro | [3H]Brimonidine (UK 14304) is a full agonist at alpha 2-adrenergic receptors. [3H]Brimonidine (UK 14304) labels at least 2 specific binding sites in human brain that both have the characteristics of an alpha 2-adrenergic binding site. GTP decreases agonist binding at both of these sites, but with different potencies at each site [1-3]. |
References |
Density | 1.8±0.1 g/cm3 |
---|---|
Boiling Point | 432.6±55.0 °C at 760 mmHg |
Melting Point | 207.5 °C |
Molecular Formula | C11H10BrN5 |
Molecular Weight | 292.135 |
Flash Point | 215.4±31.5 °C |
Exact Mass | 291.011963 |
PSA | 62.20000 |
LogP | 0.96 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Index of Refraction | 1.798 |
Storage condition | Store at RT |
Water Solubility | 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: <0.8 mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
Hazard Codes | T:Toxic; |
Risk Phrases | R25;R36/37/38 |
Safety Phrases | S26-S36-S45 |
RIDADR | UN 2811 6.1/PG 3 |
WGK Germany | - |
RTECS | VD1200000 |
Packaging Group | III |
Hazard Class | 6.1 |
HS Code | 2934999090 |
Precursor 0 | |
---|---|
DownStream 1 | |
HS Code | 2934999090 |
---|---|
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |